Blog
About

  • Record: found
  • Abstract: found
  • Article: not found

Immune checkpoint blockade: a common denominator approach to cancer therapy.

Cancer Cell

physiology, Antibodies, Monoclonal, pharmacology, therapeutic use, Antigens, CD28, antagonists & inhibitors, immunology, Antineoplastic Agents, CTLA-4 Antigen, Humans, Immunotherapy, Models, Immunological, Neoplasms, Programmed Cell Death 1 Receptor

Read this article at

ScienceOpenPublisherPMC
Bookmark
      There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

      Abstract

      The immune system recognizes and is poised to eliminate cancer but is held in check by inhibitory receptors and ligands. These immune checkpoint pathways, which normally maintain self-tolerance and limit collateral tissue damage during anti-microbial immune responses, can be co-opted by cancer to evade immune destruction. Drugs interrupting immune checkpoints, such as anti-CTLA-4, anti-PD-1, anti-PD-L1, and others in early development, can unleash anti-tumor immunity and mediate durable cancer regressions. The complex biology of immune checkpoint pathways still contains many mysteries, and the full activity spectrum of checkpoint-blocking drugs, used alone or in combination, is currently the subject of intense study. Copyright © 2015 Elsevier Inc. All rights reserved.

      Related collections

      Author and article information

      Journal
      25858804
      4400238
      10.1016/j.ccell.2015.03.001

      Comments

      Comment on this article